Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03085147 · ClinicalTrials.gov registry record · Phase 1

A Dye for the Detection of Cancer of the Tongue and Mouth

A Phase 1 study of Oral Squamous Cell Carcinoma (OSCC), sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 1
Development phase
23
Enrollment target
7
Study locations

NCT03085147 is a Phase 1 study of Oral Squamous Cell Carcinoma (OSCC) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 23 participants. The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03085147, a Phase 1 study of Oral Squamous Cell Carcinoma (OSCC), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
23 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to test if an investigational dye, called PARPi-FL, can be used to detect this type of cancer. This will be the first time that PARPi-FL is being tried in people. First, the investigators will test the safety of PARPi-FL at different doses to find out what effects, if any, it has on people. The investigators will also see which amount of PARPi-FL is best suited to detect cancers of the mouth and tongue.

Interventions

  • DRUG Olaparib

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk-Commack (Consent only) - Commack
  • Memorial Sloan Kettering Westchester (Consent Only) - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau (Consent only) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Consent Only) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Consent only) - Middletown
  • Memorial Sloan Kettering Bergen (Consent only) - Montvale

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2017-03-15
Est. Completion 2026-07
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT03085147

The ClinicalTrials.gov registry entry for NCT03085147 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Oral Squamous Cell Carcinoma (OSCC) appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.

NCT03085147 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT03085147 about?

NCT03085147 is a clinical study titled "A Dye for the Detection of Cancer of the Tongue and Mouth". The purpose of this study is to test if an investigational dye, called PARPi-FL, can be used to detect this type of cancer. This will be the first time that PARPi-FL is being tried in people. First, the investigators will test the safety of PARPi-FL at different doses to find out what effects, if an...

What is the current status of trial NCT03085147?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2017-03-15. Estimated completion is 2026-07.

What conditions does trial NCT03085147 study?

This clinical trial studies the following conditions: Oral Squamous Cell Carcinoma (OSCC).

What interventions are being tested in trial NCT03085147?

The interventions under investigation include: Olaparib (DRUG).

Who is sponsoring clinical trial NCT03085147?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03085147 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.